Steal These 3 Investing Tips From 1 of Canada’s Best Investors

There are many lessons to be learned from Stephen Jarislowsky, one of Canada’s greatest investors. Here’s why he’d avoid Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) and buy Brookfield Renewable Energy Partners L.P. (TSX:BEP.UN)(NYSE:BEP).

| More on:
The Motley Fool

Many investors these days have no idea who Stephen Jarislowsky is.

Jarislowsky is the man who was originally known as Canada’s Warren Buffett. After a short stint in the U.S. Army in World War II, and getting his MBA at Harvard, he founded money manager Jarislowsky Fraser in 1955. The firm started out as a boutique research firm, eventually expanding into managing money in the 1960s. It was a smart choice, as the firm has grown assets under management to current levels of more than $50 billion under the corporate umbrella. It is one of Canada’s largest and most influential money managers.

And through thick and thin–at least until his recent retirement–Jarislowsky was there, choosing investments and steering the company through the many obstacles the market. In 2005 Jarislowsky wrote The Investment Zoo, an autobiography that is littered with smart and actionable investment advice.

Like many of the greats, Jarislowsky’s investment philosophy is as simple as it is effective. Here are three of the man’s best investment tips.

Be conservative

In the world of penny stocks, fancy derivatives, and boom or bust tech stocks, often the tried and tested methods of building wealth get thrown out the window. Throughout all his years as an investor, Jarislowsky built his wealth by focusing on buying high-quality companies with a track record of consistently rising earnings, with a general avoidance of cyclical businesses.

An example of that kind of stock would be Brookfield Renewable Energy Partners L.P. (TSX:BEP.UN)(NYSE:BEP), which owns all sorts of hydro, wind, natural gas, and solar power-generating assets located in Canada, the United States, Europe, and Brazil. The company has a history of paying oversized dividends to investors, and currently yields 5.7%.

The company’s net profit number isn’t reliable, because of the high amounts of depreciation in the power business. But over the past four years, the company has nearly doubled its cash flow, and it has more projects in the pipeline to ensure further growth. Its management team has that proven record that Jarislowsky looked for, and there’s nothing steadier than the power business.

Start early

Most investors know the power of compound interest. Jarislowsky is perhaps an extreme example, as he still holds some of the stocks he bought while in college in the early 1940s.

Even the difference between 10 and 20 years can make a world of difference. Say you held $10,000 worth of shares that are poised to return 8% a year. After a decade, you’d have a nest egg worth $21,500 or so. But after 20 years, you’d be looking at nearly $47,000 in savings.

Now, imagine how you’d supercharge your net worth if you really scrimped and saved by putting $10,000 per year into your investments.

Don’t be afraid to sell

While Jarislowsky was a strict buy-and-hold investor, he would still periodically lighten up his exposure to certain companies, ensuring they wouldn’t leave his portfolio in a bad place if the market went down.

Perhaps investors in Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) would be wise to take this piece of advice from Jarislowsky. Over the past year, shares are up nearly 140%, and have surged more than 1,260% over the past five. While earnings have gone up considerably during that time–because of the company’s relentless acquisition spree–Valeant still trades at more than 100 times its 2014 earnings.

Earnings growth is one thing, but it’s another to pay a reasonable price for it. And right now, investors are expecting Valeant to make more monster acquisitions to really accelerate its growth. The question is whether the company can pull it off.

Fool contributor Nelson Smith has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Dividend Stocks

Canadian Dollars bills
Dividend Stocks

The TFSA Paycheque Plan: How $10,000 Can Start Paying You in 2026

A TFSA “paycheque” plan can work best when one strong dividend stock is treated as a piece of a diversified…

Read more »

A Canada Pension Plan Statement of Contributions with a 100 dollar banknote and dollar coins.
Dividend Stocks

Retirees, Take Note: A January 2026 Portfolio Built to Top Up CPP and OAS

A January TFSA top-up can make CPP and OAS feel less tight by adding a flexible, tax-free income stream you…

Read more »

senior couple looks at investing statements
Dividend Stocks

The TFSA’s Hidden Fine Print When It Comes to U.S. Investments

There's a 15% foreign withholding tax levied on U.S.-based dividends.

Read more »

young people stare at smartphones
Dividend Stocks

Is BCE Stock Finally a Buy in 2026?

BCE has stabilized, but I think a broad infrastructure focused ETF is a better bet.

Read more »

A plant grows from coins.
Dividend Stocks

Start 2026 Strong: 3 Canadian Dividend Stocks Built for Steady Cash Flow

Dividend stocks can make a beginner’s 2026 plan feel real by mixing income today with businesses that can grow over…

Read more »

senior relaxes in hammock with e-book
Dividend Stocks

2 High-Yield Dividend Stocks for Stress-Free Passive Income

These high-yield Canadian companies are well-positioned to maintain consistent dividend payments across varying economic conditions.

Read more »

Senior uses a laptop computer
Dividend Stocks

Below Average? How a 70-Year-Old Can Change Their RRSP Income Plan in January

January is the perfect time to sanity-check your RRSP at 70, because the “typical” balance is closer to the median…

Read more »

Young adult concentrates on laptop screen
Dividend Stocks

If You’re Nervous About 2026, Buy These 3 Canadian Stocks and Relax

A “relaxing” 2026 trio can come from simple, real-economy businesses where demand is easy to understand and execution drives results.

Read more »